Altered adenylate cyclase kinetics in hyperfunctioning human parathyroid glands
- PMID: 7462401
- DOI: 10.1210/jcem-52-3-499
Altered adenylate cyclase kinetics in hyperfunctioning human parathyroid glands
Abstract
Current evidence suggests that parathyroid gland adenylate cyclase is involved in the control of parathyroid hormone (PTH) secretion. Thus, the altered control of PTH release in hyperparathyroidism may relate to altered adenylate cyclase activation. Therefore, we examined adenylate cyclase kinetics in membrane preparations from hyperfunctioning human parathyroid glands and normal human and bovine parathyroid tissues. There were no differences in the affinity for ATP between enzymes of normal and pathological tissue. However, the enzyme in 10 hyperfunctioning glands showed increased affinity for Mg++. The activation constant for Mg++ (KaMg) of adenylate cyclase in normal human glands was 10.6 +/- 2 mM, a value not different from that of normal bovine parathyroid tissue (9.5 +/- 1 mM). In contrast, the adenylate cyclase in membrane preparations from three of four hyperplastic and six of seven adenomatous human glands showed a markedly reduced KaMg, ranging from 0.85-1.64 mM and from 1.58-6.46 mM, respectively. In one adenoma and one hyperplastic gland, the Ka of the enzyme for Mg++ was close to normal. The addition of guanylylimidodiphosphate or GTP to the incubation mixture increased, in a dose-dependent manner, the apparent KaMg of the enzyme in the abnormal tissue toward normal, suggesting a defective nucleotide regulatory site in the adenylate cyclase of hyperparathyroid glands. In addition, the hyperparathyroid gland enzyme was less susceptible to inhibition by calcium, requiring 0.7-1 mM Ca++ for 50% inhibition, whereas comparable inhibition of the normal adenylate cyclase was seen at 0.22-0.28 mM Ca++. We conclude that the abnormal control of PTH secretion in hyperparathyroidism may be related, at least in part, to alterations in the characteristics of parathyroid gland adenylate cyclase.
Similar articles
-
Magnesium promotes both parathyroid hormone secretion and adenosine 3',5'-monophosphate production in rat parathyroid tissues and reverses the inhibitory effects of calcium on adenylate cyclase.Endocrinology. 1982 Feb;110(2):487-95. doi: 10.1210/endo-110-2-487. Endocrinology. 1982. PMID: 6276138
-
The effects of magnesium on calcium inhibition of parathyroid adenylate cyclase.Endocrinology. 1984 Nov;115(5):1883-90. doi: 10.1210/endo-115-5-1883. Endocrinology. 1984. PMID: 6436010
-
Effects of aluminum on bovine parathyroid adenylate cyclase.Endocrinology. 1985 Oct;117(4):1456-61. doi: 10.1210/endo-117-4-1456. Endocrinology. 1985. PMID: 4029088
-
Characterization of the dopamine-responsive adenylate cyclase of bovine parathyroid cells and its relationship to parathyroid hormone secretion.Endocrinology. 1980 Dec;107(6):1776-81. doi: 10.1210/endo-107-6-1776. Endocrinology. 1980. PMID: 7428692
-
Adenylate cyclase activity in human parathyroid tissues: reduced sensitivity to suppression by calcium in parathyroid adenomas as compared with normal glands form normocalcemic subjects or noninvolved glands from hyperparathyroid subjects.Metabolism. 1981 Apr;30(4):406-11. doi: 10.1016/0026-0495(81)90123-2. Metabolism. 1981. PMID: 6782428
Cited by
-
Effect of dietary phosphorus on circulating concentrations of 1,25-dihydroxyvitamin D and immunoreactive parathyroid hormone in children with moderate renal insufficiency.J Clin Invest. 1984 Jun;73(6):1580-9. doi: 10.1172/JCI111365. J Clin Invest. 1984. PMID: 6547151 Free PMC article.
-
Secondary Hyperparthyroidism: Pathogenesis, Diagnosis, Preventive and Therapeutic Strategies.Rev Endocr Metab Disord. 2017 Mar;18(1):79-95. doi: 10.1007/s11154-017-9421-4. Rev Endocr Metab Disord. 2017. PMID: 28378123 Review.
-
Cellular physiology and pathophysiology of the parathyroid glands.World J Surg. 1991 Nov-Dec;15(6):672-80. doi: 10.1007/BF01665299. World J Surg. 1991. PMID: 1767532 Review.
-
Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients.J Clin Invest. 1984 Dec;74(6):2136-43. doi: 10.1172/JCI111639. J Clin Invest. 1984. PMID: 6549016 Free PMC article.
-
Hypocalcemia may not be essential for the development of secondary hyperparathyroidism in chronic renal failure.J Clin Invest. 1986 Oct;78(4):1097-102. doi: 10.1172/JCI112666. J Clin Invest. 1986. PMID: 3760186 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources